Sometimes success in business requires the ability to make decisions and
zig while others are zagging. It is also important to know when to stop
throwing good money after bad and call it a day. I believe those two
bromides may offer some explanation for why Merck (NYSE: MRK ) agreed to sell its Sirna assets to Alnylam Pharmaceuticals (NASDAQ: ALNY ) for a small fraction of their purchase price at a time when others like Sanofi (NYSE: SNY ) and Roche (NASDAQOTH: RHHBY ) are increasing their spending and commitment to the space.
Click here to continue:
Merck & Co., Inc. Cutting Its Losses, While Others Charge Toward RNAi
No comments:
Post a Comment